Biodexa Pharmaceuticals annual operating expenses
2015
2016
2017
2022
2023
2024
2025
Biodexa Pharmaceuticals Operating Expenses Growth & History (BDRX)
Biodexa Pharmaceuticals's operating expenses was £4.7M for fiscal 2025.
View full Biodexa Pharmaceuticals company overviewBiodexa Pharmaceuticals annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | £4.7M | £922,000 | +24.51% |
| 2024 | 2024-12-31 | £3.8M | −£566,000 | −13.08% |
| 2023 | 2023-12-31 | £4.3M | −£192,000 | −4.25% |
| 2022 | 2022-12-31 | £4.5M | — | — |
| 2017 | 2017-12-31 | £14.3M | −£11.2M | −43.90% |
| 2016 | 2016-12-31 | £25.4M | £11.2M | +78.79% |
| 2015 | 2015-12-31 | £14.2M | — | — |
Biodexa Pharmaceuticals operating expenses trends
Between the periods ended 2015-12-31 and 2025-12-31, Biodexa Pharmaceuticals's operating expenses decreased from £14.2M to £4.7M, a change of −£9.5M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biodexa Pharmaceuticals source filings ↗Community posts
Biodexa advances trial enrollment as research spending and cash use rise
Biodexa ($BDRX) reported that 92 of the planned 168 participants have entered its Serenta trial, while first-half research and development spending increased to £2.92 million from £1.67 million. Spending reflected the trial and manufacturin ...